- In November 2024, Thermo Fisher Scientific's Accelerator platform has expanded its contract research organization (CRO) and contract development and manufacturing organization (CDMO) services. This expansion will enhance Thermo Fisher's ability to support biopharma companies through the entire drug development process, from early discovery to commercial production. With the addition of new capabilities, the company can offer more integrated solutions, streamline workflows, and accelerate the timeline for drug development. This move strengthens Thermo Fisher's position in the market, providing clients with comprehensive services that span the full lifecycle of drug development and manufacturing
- In September 2024, Pharma Legacy has acquired preclinical contract research organization (CRO) BTS Research, strengthening its preclinical services and expanding its laboratory operations into North America. This acquisition will enhance Pharma Legacy’s ability to provide comprehensive drug development solutions, including toxicology, pharmacology, and pharmacokinetics studies. The expansion into North America will allow Pharma Legacy to better serve its clients in this key market and provide more efficient, localized services. The move is expected to improve Pharma Legacy’s market position, enhance its service offerings, and broaden its customer base across the pharmaceutical and biotechnology sectors
- In January 2022, Alta sciences has acquired Sinclair Research, continuing to expand its preclinical platform. This acquisition will enhance Alta sciences' capabilities in offering comprehensive preclinical services, including safety pharmacology, toxicology, and efficacy testing. With the integration of Sinclair Research’s expertise and facilities, Alta sciences aims to strengthen its position in the preclinical CRO market. The expansion will allow Alta sciences to offer an even broader range of services to its clients, ensuring quicker turnaround times and enhanced support for drug development. This strategic move is expected to benefit clients by providing more extensive, high-quality preclinical research services
